Veras V, da Cruz Paiva Lima G, da Ponte Melo I, Fernandes V, de Moura Lopes F, do Amaral C
Diabetol Metab Syndr. 2024; 16(1):216.
PMID: 39227868
PMC: 11373399.
DOI: 10.1186/s13098-024-01413-w.
da Silva M, Soares R, de Oliveira Filho A, Campos L, de Lima J, de Melo Campos J
Diabetol Metab Syndr. 2024; 16(1):145.
PMID: 38951919
PMC: 11218129.
DOI: 10.1186/s13098-024-01387-9.
Besci O, Foss de Freitas M, Guidorizzi N, Celik Guler M, Gilio D, Maung J
J Clin Endocrinol Metab. 2023; 109(3):e1204-e1224.
PMID: 37843397
PMC: 10876415.
DOI: 10.1210/clinem/dgad606.
Gokcay Canpolat A, Aslan B, Sukur Y
Hormones (Athens). 2023; 22(4):741-745.
PMID: 37491654
DOI: 10.1007/s42000-023-00469-z.
Fernandez-Pombo A, Diaz-Lopez E, Castro A, Sanchez-Iglesias S, Cobelo-Gomez S, Prado-Morana T
Cells. 2023; 12(5).
PMID: 36899861
PMC: 10000975.
DOI: 10.3390/cells12050725.
Nucleoplasmic lamin C rapidly accumulates at sites of nuclear envelope rupture with BAF and cGAS.
Kono Y, Adam S, Sato Y, Reddy K, Zheng Y, Medalia O
J Cell Biol. 2022; 221(12).
PMID: 36301259
PMC: 9617480.
DOI: 10.1083/jcb.202201024.
Adipocyte-Specific Deletion of Lamin A/C Largely Models Human Familial Partial Lipodystrophy Type 2.
Corsa C, Walsh C, Bagchi D, Foss Freitas M, Li Z, Hardij J
Diabetes. 2021; 70(9):1970-1984.
PMID: 34088712
PMC: 8576431.
DOI: 10.2337/db20-1001.
Variable Expressivity in Type 2 Familial Partial Lipodystrophy Related to R482 and N466 Variants in the LMNA Gene.
Araujo-Vilar D, Sanchez-Iglesias S, Castro A, Cobelo-Gomez S, Hermida-Ameijeiras A, Rodriguez-Carnero G
J Clin Med. 2021; 10(6).
PMID: 33803652
PMC: 8002937.
DOI: 10.3390/jcm10061259.
Efficacy of Metreleptin Treatment in Familial Partial Lipodystrophy Due to PPARG vs LMNA Pathogenic Variants.
Sekizkardes H, Cochran E, Malandrino N, Garg A, Brown R
J Clin Endocrinol Metab. 2019; 104(8):3068-3076.
PMID: 31194872
PMC: 6563798.
DOI: 10.1210/jc.2018-02787.
Lipodystrophies, dyslipidaemias and atherosclerotic cardiovascular disease.
Hussain I, Patni N, Garg A
Pathology. 2019; 51(2):202-212.
PMID: 30595509
PMC: 6402807.
DOI: 10.1016/j.pathol.2018.11.004.
Homozygous and Heterozygous Nuclear Lamin A p.R582C Mutation: Different Lipodystrophic Phenotypes in the Same Kindred.
Montenegro Jr R, Costa-Riquetto A, Fernandes V, Montenegro A, de Santana L, Jorge A
Front Endocrinol (Lausanne). 2018; 9:458.
PMID: 30177912
PMC: 6110164.
DOI: 10.3389/fendo.2018.00458.
Lipodystrophic laminopathies: Diagnostic clues.
Guillin-Amarelle C, Fernandez-Pombo A, Sanchez-Iglesias S, Araujo-Vilar D
Nucleus. 2018; 9(1):249-260.
PMID: 29557732
PMC: 5973260.
DOI: 10.1080/19491034.2018.1454167.
Treatment of Dyslipidemia in Diabetes: Recent Advances and Remaining Questions.
Chait A, Goldberg I
Curr Diab Rep. 2017; 17(11):112.
PMID: 28956258
DOI: 10.1007/s11892-017-0942-8.
Familial partial lipodystrophy, Dunnigan variety - challenges for patient care during pregnancy: a case report.
Belo S, Magalhaes A, Freitas P, Carvalho D
BMC Res Notes. 2015; 8:140.
PMID: 25885670
PMC: 4403845.
DOI: 10.1186/s13104-015-1065-4.
LMNA mutations, skeletal muscle lipid metabolism, and insulin resistance.
Boschmann M, Engeli S, Moro C, Luedtke A, Adams F, Gorzelniak K
J Clin Endocrinol Metab. 2010; 95(4):1634-43.
PMID: 20130076
PMC: 2853996.
DOI: 10.1210/jc.2009-1293.
The role of LMNA in adipose: a novel mouse model of lipodystrophy based on the Dunnigan-type familial partial lipodystrophy mutation.
Wojtanik K, Edgemon K, Viswanadha S, Lindsey B, Haluzik M, Chen W
J Lipid Res. 2009; 50(6):1068-79.
PMID: 19201734
PMC: 2681389.
DOI: 10.1194/jlr.M800491-JLR200.
Reduced expression of lamin A/C correlates with poor histological differentiation and prognosis in primary gastric carcinoma.
Wu Z, Wu L, Weng D, Xu D, Geng J, Zhao F
J Exp Clin Cancer Res. 2009; 28:8.
PMID: 19144202
PMC: 2632624.
DOI: 10.1186/1756-9966-28-8.
Heterozygous CAV1 frameshift mutations (MIM 601047) in patients with atypical partial lipodystrophy and hypertriglyceridemia.
Cao H, Alston L, Ruschman J, Hegele R
Lipids Health Dis. 2008; 7:3.
PMID: 18237401
PMC: 2276215.
DOI: 10.1186/1476-511X-7-3.
Familial partial lipodystrophy associated with compound heterozygosity for novel mutations in the LMNA gene.
Savage D, Soos M, Powlson A, ORahilly S, McFarlane I, Halsall D
Diabetologia. 2004; 47(4):753-6.
PMID: 15298354
DOI: 10.1007/s00125-004-1360-4.
Insulin resistance in human partial lipodystrophy.
Hegele R
Curr Atheroscler Rep. 2000; 2(5):397-404.
PMID: 11122771
DOI: 10.1007/s11883-000-0078-0.